Search Results

You are looking at 1 - 2 of 2 items for

  • Author: Rosalyn A. Juergens x
  • Refine by Access: All x
Clear All Modify Search
Full access

Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?

Rosalyn A. Juergens and Julie R. Brahmer

Lung cancer is the most common cancer worldwide, accounting for 1.2 million new cases annually. Despite aggressive local management of patients diagnosed with early-stage disease (stages I–IIIA), more than half of patients who have undergone surgical resection will die from complications caused by recurrent lung cancer. Over the past 5 years, results from several large trials assessing the use of adjuvant platinum-based chemotherapy in non-small cell lung cancer have become available. This article reviews the data from the most prominent of these trials and focuses on how the combination of cisplatin and etoposide has been evaluated for use in the adjuvant setting. Cisplatin-based therapy has now been shown to provide a significant survival benefit in several trials and recent meta-analyses. These data have changed the paradigm for how early-stage lung cancer is managed.

Full access

Combined Modality Therapy of Esophageal Cancer

Rosalyn A. Juergens and Arlene Forastiere

Edited by Kerrin G. Robinson

Esophageal cancer is a deadly disease. Only one third of patients with localized disease experience long-term survival. Over the past 20 years, investigators have evaluated neoadjuvant strategies to improve the outcomes of surgical management. Chemotherapy and radiation have been evaluated individually and in combination for preoperative management of patients with localized esophageal cancer. This article provides a critical review of the data on multimodality approaches to the management of esophageal cancer.